499 related articles for article (PubMed ID: 31372066)
21. Recent Advances in the Therapeutic Management of Advanced Systemic Mastocytosis.
Veitch S; Radia DH
Diagnostics (Basel); 2023 Dec; 14(1):. PubMed ID: 38201389
[TBL] [Abstract][Full Text] [Related]
22. [Therapeutically relevant mutations in the receptor tyrosine kinase KIT in mastocytosis].
Sotlar K
Verh Dtsch Ges Pathol; 2007; 91():169-76. PubMed ID: 18314612
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis.
Reiter A; Schwaab J; DeAngelo DJ; Gotlib J; Deininger MW; Pettit KM; Alvarez-Twose I; Vannucchi AM; Panse J; Platzbecker U; Hermine O; Dybedal I; Lin HM; Rylova SN; Ehlert K; Dimitrijević S; Radia DH
Blood Adv; 2022 Nov; 6(21):5750-5762. PubMed ID: 35640224
[TBL] [Abstract][Full Text] [Related]
24. Kit Mutations: New Insights and Diagnostic Value.
Falchi L; Verstovsek S
Immunol Allergy Clin North Am; 2018 Aug; 38(3):411-428. PubMed ID: 30007460
[TBL] [Abstract][Full Text] [Related]
25. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis.
Erben P; Schwaab J; Metzgeroth G; Horny HP; Jawhar M; Sotlar K; Fabarius A; Teichmann M; Schneider S; Ernst T; Müller MC; Giehl M; Marx A; Hartmann K; Hochhaus A; Hofmann WK; Cross NC; Reiter A
Ann Hematol; 2014 Jan; 93(1):81-8. PubMed ID: 24281161
[TBL] [Abstract][Full Text] [Related]
26. The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease.
Hoermann G; Gleixner KV; Dinu GE; Kundi M; Greiner G; Wimazal F; Hadzijusufovic E; Mitterbauer G; Mannhalter C; Valent P; Sperr WR
Allergy; 2014 Jun; 69(6):810-3. PubMed ID: 24750133
[TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial.
DeAngelo DJ; Radia DH; George TI; Robinson WA; Quiery AT; Drummond MW; Bose P; Hexner EO; Winton EF; Horny HP; Tugnait M; Schmidt-Kittler O; Evans EK; Lin HM; Mar BG; Verstovsek S; Deininger MW; Gotlib J
Nat Med; 2021 Dec; 27(12):2183-2191. PubMed ID: 34873347
[TBL] [Abstract][Full Text] [Related]
28. Targeting Sphingosine Kinase Isoforms Effectively Reduces Growth and Survival of Neoplastic Mast Cells With D816V-KIT.
Bandara G; Muñoz-Cano R; Tobío A; Yin Y; Komarow HD; Desai A; Metcalfe DD; Olivera A
Front Immunol; 2018; 9():631. PubMed ID: 29643855
[TBL] [Abstract][Full Text] [Related]
29. A new humanized in vivo model of KIT D816V+ advanced systemic mastocytosis monitored using a secreted luciferase.
Bibi S; Zhang Y; Hugonin C; Mangean MD; He L; Wedeh G; Launay JM; Van Rijn S; Würdinger T; Louache F; Arock M
Oncotarget; 2016 Dec; 7(50):82985-83000. PubMed ID: 27783996
[TBL] [Abstract][Full Text] [Related]
30. Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.
Ustun C; DeRemer DL; Akin C
Leuk Res; 2011 Sep; 35(9):1143-52. PubMed ID: 21641642
[TBL] [Abstract][Full Text] [Related]
31. New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis.
Reiter A; George TI; Gotlib J
Blood; 2020 Apr; 135(16):1365-1376. PubMed ID: 32106312
[TBL] [Abstract][Full Text] [Related]
32. The new tool "
Shomali W; Gotlib J
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):127-136. PubMed ID: 30504301
[TBL] [Abstract][Full Text] [Related]
33. Target Therapies for Systemic Mastocytosis: An Update.
Sciumè M; De Magistris C; Galli N; Ferretti E; Milesi G; De Roberto P; Fabris S; Grifoni FI
Pharmaceuticals (Basel); 2022 Jun; 15(6):. PubMed ID: 35745657
[TBL] [Abstract][Full Text] [Related]
34. Mastocytosis and related entities: a practical roadmap.
Beyens M; Elst J; van der Poorten ML; Van Gasse A; Toscano A; Verlinden A; Vermeulen K; Maes MB; Oude Elberink JNGH; Ebo D; Sabato V
Acta Clin Belg; 2023 Aug; 78(4):325-335. PubMed ID: 36259506
[TBL] [Abstract][Full Text] [Related]
35. Response and progression on midostaurin in advanced systemic mastocytosis:
Jawhar M; Schwaab J; Naumann N; Horny HP; Sotlar K; Haferlach T; Metzgeroth G; Fabarius A; Valent P; Hofmann WK; Cross NCP; Meggendorfer M; Reiter A
Blood; 2017 Jul; 130(2):137-145. PubMed ID: 28424161
[TBL] [Abstract][Full Text] [Related]
36. Available and emerging therapies for bona fide advanced systemic mastocytosis and primary eosinophilic neoplasms.
Gotlib J
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):34-46. PubMed ID: 36485158
[TBL] [Abstract][Full Text] [Related]
37. Mastocytosis: state of the art.
Horny HP; Sotlar K; Valent P
Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
[TBL] [Abstract][Full Text] [Related]
38. Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management.
Pardanani A
Am J Hematol; 2019 Mar; 94(3):363-377. PubMed ID: 30536695
[TBL] [Abstract][Full Text] [Related]
39. Advanced systemic mastocytosis-Revised classification, new drugs and how we treat.
Pardanani A; Reichard K; Tefferi A
Br J Haematol; 2024 Feb; 204(2):402-414. PubMed ID: 38054381
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial.
Gotlib J; Reiter A; Radia DH; Deininger MW; George TI; Panse J; Vannucchi AM; Platzbecker U; Alvarez-Twose I; Mital A; Hermine O; Dybedal I; Hexner EO; Hicks LK; Span L; Mesa R; Bose P; Pettit KM; Heaney ML; Oh ST; Sen J; Lin HM; Mar BG; DeAngelo DJ
Nat Med; 2021 Dec; 27(12):2192-2199. PubMed ID: 34873345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]